September 15, 2010
National Poll Finds Seniors, Women and Americans From Across the Political Spectrum Reject FDA’s Consideration of Cost in Drug Approval Process
63% of Americans oppose a pending FDA decision that bases cancer treatment options on cost; 71% are more likely to vote against candidates who support the FDA decision
(Washington, DC) – 60 Plus, a national seniors-advocacy organization, released findings from a national poll demonstrating that Americans reject efforts by the Food and Drug Administration (FDA) to include “cost factors” as part of the drug approval process. In a case that many observers believe represents an emerging model for rationing care, the FDA is preparing to “de-label” Avastin, a drug used primarily for late stage cancer patients in part because of cost concerns. Such an action could result in Avastin coverage for breast cancer patients being denied by Medicare, Medicaid and private insurance plans, while leaving the drug available to only those who can afford it.
“Let this poll be a warning to politicians, voters reject rationing; period, and the recent case of the FDA determining a breast cancer drug is too expensive, is just the tip of the rationing iceberg. Politicians who put a price on life will absolutely pay a price at the polls,” said Jim Martin, the Chairman of 60 Plus.
Pat Boone, legendary entertainer and spokesman for 60 Plus, said, “In 2010, millions of seniors will be showing up to vote in droves. Tens of thousands of seniors rely on cancer treatments like the one the FDA is currently saying is too expensive to extend life and preserve hope. If Washington denies their right to the best available treatments, Washington can expect to hear from them in November.”
The poll, commissioned by 60 Plus and fielded by Logos Communications from September 8 to September 10, 2010, clearly demonstrates that while Americans remain mostly opposed to the recently passed healthcare reform bill, they are wholly united against the prospect of healthcare rationing that puts a price a human life.
Public Opinion on Healthcare Reform & Rationing
Public Opinion on the FDA & the Avastin Case
This survey data was collected by Logos Communications via internet surveys of 819 registered American voters from September 8 to September 10, 2010. The margin of sampling error is +/- 3.5% with a 95% level of confidence, with the sample accurately reflecting the American voter pool.